UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 85 filers reported holding UROGEN PHARMA LTD in Q3 2019. The put-call ratio across all filers is 1.12 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $136,808 | +40.4% | 9,765 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $97,466 | +16.0% | 9,417 | -2.8% | 0.00% | – |
| Q1 2022 | $84,000 | -15.2% | 9,685 | -6.6% | 0.00% | – |
| Q4 2021 | $99,000 | -45.0% | 10,367 | -2.9% | 0.00% | -100.0% |
| Q3 2021 | $180,000 | +7.8% | 10,676 | -2.3% | 0.00% | 0.0% |
| Q2 2021 | $167,000 | -24.1% | 10,930 | -3.2% | 0.00% | 0.0% |
| Q1 2021 | $220,000 | +8.4% | 11,296 | +0.3% | 0.00% | 0.0% |
| Q4 2020 | $203,000 | -9.4% | 11,267 | -2.8% | 0.00% | 0.0% |
| Q3 2020 | $224,000 | -27.7% | 11,591 | -2.2% | 0.00% | 0.0% |
| Q2 2020 | $310,000 | +56.6% | 11,853 | +6.9% | 0.00% | 0.0% |
| Q1 2020 | $198,000 | -49.5% | 11,091 | -5.5% | 0.00% | -50.0% |
| Q4 2019 | $392,000 | +39.0% | 11,733 | -0.8% | 0.00% | +100.0% |
| Q3 2019 | $282,000 | -34.1% | 11,831 | -0.7% | 0.00% | -50.0% |
| Q2 2019 | $428,000 | – | 11,913 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 1,111,050 | $9,099,000 | 4.23% |
| GREAT POINT PARTNERS LLC | 873,424 | $7,153,000 | 1.72% |
| Wildcat Capital Management, LLC | 533,139 | $4,366,000 | 1.45% |
| Opaleye Management Inc. | 238,670 | $1,955,000 | 0.88% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,949,489 | $24,156,000 | 0.44% |
| Annandale Capital, LLC | 84,331 | $691,000 | 0.27% |
| Yahav Achim Ve Achayot - Provident Funds Management Co Ltd. | 25,330 | $206,000 | 0.18% |
| RTW INVESTMENTS, LP | 857,464 | $7,023,000 | 0.18% |
| Harel Insurance Investments & Financial Services Ltd. | 1,025,611 | $8,400,000 | 0.18% |
| BENDER ROBERT & ASSOCIATES | 41,131 | $337,000 | 0.13% |